Based on the profound effect of RSK inhibition in suppressing tumor growth in vitro, its in vivo efficacy was assessed investigating a BRAFMut (451LU) and an NF-1LOF (MeWo) subcutaneous melanoma xenograft model. Here, RPS6KA3 is linked to neoplasm.